INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

CagriSema

CagriSema is the development name for the cagrilintide–semaglutide combination. It combines amylin and GLP-1 pathways and has Phase 3 trial evidence.

Single conceptual cagrisema carton labeled Illustration and Investigational.
Conceptual CagriSema carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.

CagriSema is the development name for the cagrilintide–semaglutide combination. It combines amylin and GLP-1 pathways and has Phase 3 trial evidence.

REDEFINE 1 studied adults without diabetes, while REDEFINE 2 studied adults with type 2 diabetes. Their average weight changes concern different populations. Treatment-policy results also need to be distinguished from estimates assuming continued treatment.

A marketing application is not an approval. The September 2026 sponsor status is current evidence of development, not an independent regulator decision.

This record is not advice to combine separate semaglutide and cagrilintide products. FDA identifies concerns about unapproved products, and a seller’s use of the development name cannot establish equivalence to the trial combination.

Regulatory status checked on 3 October 2026

United States: Sponsor announced an FDA application on 18 December 2025 and still described CagriSema as investigational on 30 September 2026. Subsequent FDA approval has not been verified.

European Union: EU marketing authorisation has not been verified in this review. No claim of an approved EU combination product is made.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. CagriSema US application announcement ↗
  2. September 2026 CagriSema development status ↗
  3. REDEFINE 1 combination-treatment trial ↗
  4. REDEFINE 2 trial in type 2 diabetes ↗
  5. FDA GLP-1 safety communication ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

REDEFINE 1

NCT05567796 · Cagrisema profile

Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
active not recruiting
Registry enrollment
3400 (estimated)
Published analysis population
3417
Analysis time point
68 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry estimated enrollment 3400 is a planning value; the published randomized population is 3417.

Published mean body-weight change at 68 weeks · treatment-policy (intention-to-treat)
Historical trial armMean change from baseline
cagrilintide 2.4 mg plus semaglutide 2.4 mg trial arm-20.4%
placebo-3.0%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy